The Cysteinome of Protein Kinases as a Target in Drug Development-Reference-Cited by-同舟云学术

The Cysteinome of Protein Kinases as a Target in Drug Development

Published:2018-02-02 Issue:16 Volume:57 Page:4372-4385
ISSN:1433-7851
Container-title:Angewandte Chemie International Edition
language:en
Short-container-title:Angew. Chem. Int. Ed.

Author:

Chaikuad Apirat¹²,Koch Pierre³^ORCID,Laufer Stefan A.³⁴,Knapp Stefan¹⁵²⁶^ORCID

Affiliation:

1. Nuffield Department of Clinical Medicine; Structural Genomics Consortium and Target Discovery Institute; University of Oxford, Old Road Campus Research Building; Roosevelt Drive Oxford OX3 7DQ UK

2. Institute for Pharmaceutical Chemistry; Goethe-University; Max-von-Laue-Strasse 9 60438 Frankfurt am Main Germany

3. Department of Pharmaceutical/Medicinal Chemistry; Eberhard-Karls-University Tübingen; Auf der Morgenstelle 8 72076 Tübingen Germany

4. German Cancer Consortium DKTK, Standort Tübingen; Germany

5. German Cancer Consortium DKTK, Standort Frankfurt/Mainz; Germany

6. Structural Genomics Consortium and Buchmann Institute for Molecular Life Sciences; Johann Wolfgang Goethe-University; Max-von-Laue-Strasse 15 60438 Frankfurt am Main Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

General Chemistry,Catalysis

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/anie.201707875/fullpdf

Reference131 articles.

1. Address in Pathology ON CHEMOTHERAPEUTICS:

2. The resurgence of covalent drugs

3. Designing Irreversible Inhibitors-Worth the Effort?

4. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

2. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

3. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies;Journal of Advanced Research;2024-09

4. Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor;Journal of Medicinal Chemistry;2024-07-16

5. Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53;Drug Design, Development and Therapy;2024-07